1Packer M.The neurohumoral hypothesis:a theory to explain the mechanism of disease progression in heart failure[J].J Am Coll Cardiol,1992,20:248-254.
2Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary.A report of the ACC/AHA task force on practice guidelines[J].J Am Coll Cardiol,2001,38:2101-2113.
6Waggstein F,Bristow MR.Beneficial effect of metoprolol in idiopathic cardioaypathy[J].Lancet,1993,342(8885):1441-1446.
7Lechat PP,Packer M,Chalon S,et al.Clinical effects of β-adrenergic blockage in chronic heart failure:a meta-analysis of double-blind,placebo-controlled randomized trials[J].Circulation,1998,98:1184-1191.
8CIBISⅡ Investigators and Committees:The Cardiac Insufficiency Bisoprolol StudyⅡ(CIBISⅡ):a randomized trial[J].Lancet,1999,353(9146):9-13.
9MERIT HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Trial in Congestive Heart Failure (MERIT HF)[J].Lancet,1999,353:2001-2007.
10Packer M,Coats AJ,Fowler MB,et al.Effects of Carvedilol on survival in severe chronic heart failure[J].N Engl J Med,2001,344:1651-1658.
二级参考文献10
1Beta-Blocker Evaluation of Survival Trial Investigators.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure[].The New England Journal of Medicine.2001
2Cohn JN,Tognoni G.A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure[].The New England Journal of Medicine.2001
3Feldman RD.Adrenergic receptor polymorphisms and cardiac function(and dysfunction): a failure to communicate[].Circulation.2001
4Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary.A report of the ACC/AHA task force on practice guidelines[].Journal of the American College of Cardiology.2001
5MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Trial in Congestive Heart Failure(MERIT-HF)[].The Lancet.1999
6Exner DV,Dries DL,Domanski MJ.Lesser response to angiotensinconverting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction[].The New England Journal of Medicine.2001
7Swedberg K,Bristow MR,Cohn JN,et al.Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure[].Circulation.2002
8Packer M,Coats AJ,Fowler MB,et al.Effects of carvedilol on survival in severe chronic heart failure[].The New England Journal of Medicine.2001
9Wikstrand J,Hjalmarson A,Waagstein F,et al.Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF)[].Journal of the American College of Cardiology.2002
10Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999
2[3]Hjalmarson A,Kneider M,Wagstein F,et al.The role of betsblockers in left ventriculer dysfunction and heart failare[J].Drugs,1997,54(5):501.
3[4]Constant J.A review of why and hew we may use beta-blockers in congestive heart failure[J].Chest,1998,113(3):800.
4[5]Suwam,lto T,Otake Y,et al.Effect of beta-blocker treatment in dialated cardiomanyopathy with bredyarrhythmias[J].Jpn Cire J,1998,62(10):765.
5[6]Andersson B,Stromblad SO,I.omsky M,et al.Heart rate dependency of cardiac performance in heart failure patients treated with metoprolol[J].Ear heart J,1999,20(8):575.
6[7]Janssen K,Dalalstrom U,karlberg B,et al.The circulating renin-angiotensin system duning.Treatment with metoprolol or eaptoprisl inpatients with heart failure due to nonischacemidilated cardiomyopathy[J].J Intern Med,1999,245(5):435.
7[8]Gwathmey JK,Kim CS,Hajjar RI,et al.Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol[J].Am J Physiol,1999,276(4):1678.
